Navigation Links
A step forward in virology

The vaccinia virus has a problem: it is a giant among viruses and needs a special strategy in order to infiltrate a cell and reproduce. Professor Ari Helenius and Postdoc Jason Mercer from ETH Zurichs Institute for Biochemistry have now discovered what this strategy is. In the process, they stumbled upon new and surprising findings.

The invasion strategy

In order to infiltrate a cell, the vaccinia virus exploits the cellular waste disposal mechanism. When a cell dies, other cells in the vicinity ingest the remains, without needing waste disposal experts such as macrophages. The cells recognize the waste via a special molecule, phosphatidylserine, which sits on the inner surface of the double membrane of cells. This special molecule is pushed out as soon as the cell dies and is broken into parts. The vaccinia virus itself also car-ries this official waste tag on its surface. The substance accumulates on the shell of vaccinia viruses, Jason Mercer explained. The pathogen disguises itself as waste material and tricks cells into digesting it, just as they normally would with the remains of dead cells. As the immune response is simultaneously sup-pressed, the virus can be ingested as waste without being noticed.

The uptake into the cell itself is via macropinocytosis. The ETH Zurich researchers have demonstrated that the vaccinia virus moves along actin-rich filamentous extensions towards the cell. As soon as they impinge upon the cell membrane, an evagination forms, a bleb. The virus itself is the trigger for the formation of the evagination. Using a messenger substance to knock on the door, the virus triggers a signaling chain reaction inside the cell so that the bleb forms, catches the virus and smuggles it into the cell.

Proteins as unsuspecting allies

The viruses are the Trojan horses that want to enter Troy; the Trojans are the many proteins that transmit the signals and open the city gates to the unwelcome guest, Ari Helenius said. Aided by Professor Lukas Pelkmans team, Ja-son Mercer examined over 7000 different proteins in order to find out not only which Trojans let the virus in, but which as well are chiefly involved in the supply chain. Using definitive methods, the researchers de-activated each one of the suspected proteins to examine their function,and narrowed the vast number of proteins down to 140 potential culprits. The enzyme kinase PAK1 turned out to be an especially helpful citizen of Troy. Without PAK1, the pathogens trick did not work and the cell did not form any evaginations.

Until now, very little has been known about the mechanism vaccinia viruses use to infiltrate a cell. Professor Helenius, whose research objective is to find out what methods and strategies various different viruses employ to invade somatic cells, clarified This strategy is a new one. Other viruses, such as herpes, adeno and H1 viruses use macropinocytosis. However the vaccinia virus is the first one identified that uses apoptotic mimicry as an entry strategy.

Knowledge of the virus strategies and the signal proteins involved in the ingestion of a virus by a cell is crucial to finding and developing new agents against the pathogens. Until now, antiviral medication has targeted the virus itself. Ari Helenius, however, is looking for substances that interrupt the signaling chain and halt the communication between the virus and the cell. If the cell does not ingest a virus, the virus cannot reproduce and is quickly eliminated by the immune system. This process also has another big advantage: Viruses cannot adapt to the obstruction of the signal chain all that quickly, he said.

Smallpox: a bioterrorist attack?

The vaccinia virus belongs to a family of particularly dangerous viruses, namely the pox viruses. The most infamous member, Variola, the casitive agent of smallpox constituted a global pandemic disease in the Middle Ages, causing the deaths of millions of people, especially among the indigenous population of North America who became infected by European settlers. Pox was the first viral disease against which a vaccination was developed. In 1771, the first rudimentary vaccine was produced from cowpox viruses, which protected people from the sequelae of the disease. Since 1978, the disease has been classed as eradicated and officially is preserved in only two laboratories; one in Atlanta, the other in Novosibirsk. US authorities, however, fear bioterrorist attacks with pox viruses. Research on these dangerous pathogens is thus encouraged.


Contact: Jason Mercer
ETH Zurich/Swiss Federal Institute of Technology

Related biology news :

1. Is hybridoma production about to take a quantum leap forward?
2. Graduate Education in Physics: Which Way Forward?
3. Karen Beemon wins the 2007 Retrovirology Prize
Post Your Comments:
(Date:11/17/2015)...  Vigilant Solutions announces today that Mr. Dick ... --> --> Mr. ... partnership at TPG Capital, one of the largest global ... in revenue.  He founded and led TPG,s Operating Group, ... from 1997 to 2013.  In his first role, he ...
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/11/2015)... 2015   MedNet Solutions , an innovative SaaS-based eClinical ... is pleased to announce that it will be a Sponsor ... event, to be held November 17-19 in Hamburg ... demonstrations of iMedNet , MedNet,s easy-to-use, proven ... has been able to deliver time and cost savings ...
Breaking Biology News(10 mins):
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon ... over 2,000 technical presentations offered in symposia, oral sessions, workshops, awards, and posters. ... a wide range of applications such as, but not limited to, biotechnology, biomedical, ...
(Date:11/25/2015)... --> ... 2020 report analyzes that automating biobanking workflow will ... long-term samples, minimizing manual errors, improving the workflow ... errors such as mislabeling or inaccurate sample barcoding ... a vital role in blood fractionation, DNA extraction, ...
(Date:11/25/2015)... and HOLLISTON, Mass. , ... Inc. (Nasdaq: HART ), a biotechnology company developing ... CEO Jim McGorry will present at the ... 1, 2015 at 2:30 p.m. PT. The presentation will ... for 30 days. Management will also be available at ...
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, ... will participate in a fireside chat discussion at the ... New York . The discussion is scheduled for ... .  A replay will be available ... Contact:McDavid Stilwell  , Julie NormartVP, Corporate Communications and ...
Breaking Biology Technology: